Aim The aim of this study was to evaluate trends in visual impairment certification due to age-related macular degeneration (ARMD) in the Leeds metropolitan area between 2005 and 2010. Methods In this retrospective study, the primary causes of visual impairment certification in the Leeds metropolitan area between 2005 and 2010 were reviewed. ARMD was considered to be the cause of certification when recorded as the primary factor contributing to visual impairment in one or both eyes. The incidence of visual impairment certification due to ARMD was calculated using population estimates from the Office of National Statistics. Results ARMD was the primary cause of visual impairment certification in all study years, accounting for 58.7 and 50.8% of certifications in 2005 and 2010, respectively. For the same period, the incidence of certification due to ARMD fell from 364 to 248 per million population per year. This was largely the result of a fall in the incidence of visual impairment certification due to neovascular ARMD from 225 to 137 per million population per year, beginning in 2008 after the introduction of a local commissioning policy on the use of intra-vitreal ranibizumab. Conclusion The incidence of visual impairment certification due to ARMD in the Leeds metropolitan area appears to be falling. This is largely the result of a decrease in certification secondary to neovascular ARMD. This represents a change in the previously described trend for ARMD visual impairment certification.
Introduction
Age-related macular degeneration (ARMD) is the major cause of sight impairment in older adults in the United Kingdom. 1 It can be subclassified into atrophic ARMD (GA) and neovascular ARMD (NVARMD). 2, 3 Although there is currently no effective treatment for GA, NVARMD can be treated with intra-vitreal ranibizumab (Lucentis, Novartis Pharmaceuticals, Camberley, UK). Ranibizumab has been demonstrated to stabilise visual acuity in the majority of cases and was approved by the US Food and Drug Administration (FDA) in 2004 and licensed for use in Europe in 2006. 4 Following a local commissioning policy, ranibizumab was available as a treatment for NVARMD in Leeds before the approval by the National Institute for Clinical Excellence in August 2008.
Previous studies have indicated a continuous increase in certifiable visual impairment secondary to ARMD, between 1933 and 1991, coincident with the increasing age of the population. 5 In this study, we aimed to evaluate trends in the visual impairment certification due to ARMD in the Leeds metropolitan area between 2005 and 2010.
Methods

Sources of data
The primary cause of visual impairment certification was collected retrospectively in 2005 using the BD8 form. Following a change in UK practice, the same data was collected prospectively from Leeds Adult Social Care for the years 2008, 2009, and 2010 using the certificate of visual impairment (CVI) form. NVARMD was considered to be the cause of certification when recorded as the primary cause of visual impairment in one or both eyes. 
Calculation of incidence
Results
The total number of visual impairment certifications was found to be decreasing between the study years. 
Discussion
In this study, the incidence of visual impairment certification secondary to ARMD between 2005 and 2010 appears to be falling. This seems to be the result of a reduction in the number of certifications secondary to NVARMD, as the number of certifications secondary to GA remained more stable. This downward trend is in contrast to prior predictions 5, 6 and was seen despite a 7% increase in the total population of the study area. This follows the local introduction of ranibizumab as a treatment for NVARMD in 2007 (Figure 1 ).
Since Sorsby first published an analysis of the number of blind people in England and Wales, 7, 8 visual impairment certification has served as a mechanism for social care allocation. The original BD8 form was introduced by Department of Health in 1983 and was replaced by the CVI form in 2003. 9, 10 The current criteria for visual impairment certification are summarised in Table 1 . Certification is voluntary and the limitations of using visual impairment certification data to provide incident data have been noted before. [11] [12] [13] Despite these limitations, certifications can be used as a marker of disease in a population and may also be used to evaluate the impact of a new intervention or treatment.
Between 2005 and 2010, the total number of certifications for the Leeds metropolitan area fell by 18%. Although this is a trend seen nationally, the number of certifications for GA and two of the other, common, local causes of visual impairment certification, namely 14 This suggests that at least some of the reduction in the total number of certifications may be the result of a reduction in the contribution of NVARMD. During the study period, the most significant innovation was the introduction of ranibizumab as a first-line treatment for NVARMD locally. Through a local commissioning policy this was introduced progressively between 2007 and 2008, in advance of NICE guidance. This study cannot determine whether the decrease in NVARMD certification is a direct consequence of this policy. For some patients treated with ranibizumab, late visual loss is secondary to GA. 15 One hypothesis was that a fall in the number of certifications due to NVARMD would be offset by a rise in certifications due to GA. This was not apparent between 2005 and 2010, although it may be a trend seen with longer term evaluation. It may have been masked by errors in recording the primary cause of visual impairment. The current CVI form permits the recording of multiple causes of visual impairment. An individual treated for NVARMD may experience progressive visual loss due to GA, and this could create confusion as to the primary cause of certification.
This study has a number of potential weaknesses. In addition to those already described, the use of certification data can only provide a minimum incidence of visual impairment due to ARMD. The strengths include the availability of data for a number of years and prospective data collection since 2007. For the population at risk, there is unlikely to have been significant movement into or from the Leeds metropolitan area. Although under-reporting remains a potential problem, there has not been a major change in the number of staff available to complete the CVI forms during the study period. For these reasons, it is likely that the comparison of incidence across the study period is valid. It would be interesting to see whether there are similar trends reported in other units or nationally.
Conclusion
The incidence of visual impairment certification due to ARMD in the Leeds metropolitan area fell between 2005 and 2010. This was largely the result of a decrease in visual impairment certification secondary to NVARMD, following the European licence for ranibizumab and the introduction of a local commissioning policy. This represents a change in the previously described trend for ARMD certification. Further studies are needed to establish the development of the trend with time and the relevance to a larger population area.
Summary
What was known before K Previous studies show the incidence of ARMD to be increasing, in keeping with ageing population.
K Visual impairment certifications can be used as a marker for disease in a population and may be used to evaluate new intervention or treatment.
K During the period of our study ranibizumab has been introduced as first-line treatment for NVARMD, and has been shown to stabilise vision in the majority of patients.
What this study adds K The incidence of visual impairment certification due to ARMD decreased between 2005 and 2010, despite an increase in the total population of Leeds.
K The decrease was mostly secondary to decline in NVARMD.
K The incidence of GA did not show such a trend and appeared more stable.
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